Literature DB >> 15361653

Eradication of mycoplasma contaminations.

Cord C Uphoff1, Hans G Drexler.   

Abstract

Mycoplasma contaminations have a multitude of effects on cultured cell lines that can potentially influence the results of experiments and pollute bioactive substances used in human medicine. The elimination of mycoplasma contaminations in cell cultures has become a practical alternative to discarding and re-establishing important or irreplaceable cell lines. Different quinolones, tetracyclins, and macrolides shown to have strong antimycoplasma properties are employed for the decontamination. We provide detailed descriptions to assure eradication of mycoplasma, to prevent formation of resistant mycoplasma strains, and to cure heavily contaminated and damaged cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during or after the treatment have been detected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15361653     DOI: 10.1385/1-59259-838-2:025

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro.

Authors:  Craig Gedye; Tracy Cardwell; Nektaria Dimopoulos; Bee Shin Tan; Heather Jackson; Suzanne Svobodová; Matthew Anaka; Andreas Behren; Christopher Maher; Oliver Hofmann; Winston Hide; Otavia Caballero; Ian D Davis; Jonathan Cebon
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

2.  Efficiency of Plasmocin™ on various mammalian cell lines infected by mollicutes in comparison with commonly used antibiotics in cell culture: a local experience.

Authors:  Vahid Molla Kazemiha; Shahram Azari; Amir Amanzadeh; Shahin Bonakdar; Morteza Shojaei Moghadam; Mahdi Habibi Anbouhi; Susan Maleki; Nahid Ahmadi; Tahmineh Mousavi; Mohammad Ali Shokrgozar
Journal:  Cytotechnology       Date:  2011-08-25       Impact factor: 2.058

3.  Mycoplasma contamination of murine embryonic stem cells affects cell parameters, germline transmission and chimeric progeny.

Authors:  Kyriaki Markoullis; Diana Bulian; Gabriele Hölzlwimmer; Leticia Quintanilla-Martinez; Katrin-Janine Heiliger; Horst Zitzelsberger; Hagen Scherb; Josef Mysliwietz; Cord C Uphoff; Hans G Drexler; Thure Adler; Dirk H Busch; Jörg Schmidt; Esther Mahabir
Journal:  Transgenic Res       Date:  2008-09-26       Impact factor: 2.788

4.  Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.

Authors:  Martin Peifer; Jonathan Weiss; Martin L Sos; Mirjam Koker; Stefanie Heynck; Christian Netzer; Stefanie Fischer; Haridas Rode; Daniel Rauh; Jörg Rahnenführer; Roman K Thomas
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

5.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Authors:  Martin L Sos; Kathrin Michel; Thomas Zander; Jonathan Weiss; Peter Frommolt; Martin Peifer; Danan Li; Roland Ullrich; Mirjam Koker; Florian Fischer; Takeshi Shimamura; Daniel Rauh; Craig Mermel; Stefanie Fischer; Isabel Stückrath; Stefanie Heynck; Rameen Beroukhim; William Lin; Wendy Winckler; Kinjal Shah; Thomas LaFramboise; Whei F Moriarty; Megan Hanna; Laura Tolosi; Jörg Rahnenführer; Roel Verhaak; Derek Chiang; Gad Getz; Martin Hellmich; Jürgen Wolf; Luc Girard; Michael Peyton; Barbara A Weir; Tzu-Hsiu Chen; Heidi Greulich; Jordi Barretina; Geoffrey I Shapiro; Levi A Garraway; Adi F Gazdar; John D Minna; Matthew Meyerson; Kwok-Kin Wong; Roman K Thomas
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

6.  Decontamination of mycoplasma-contaminated Orientia tsutsugamushi strains by repeating passages through cell cultures with antibiotics.

Authors:  Motohiko Ogawa; Tsuneo Uchiyama; Masaaki Satoh; Shuji Ando
Journal:  BMC Microbiol       Date:  2013-02-08       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.